Statistical methods in infectious disease trials
The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.
Non-inferiority trial design
Risk difference
Cochran-Mantel-Haenszel test
ANCOVA
Hazard ratio
Score-based CI for proportions (Miettinen-Nurminen, Newcombe, Wilson)
Fisher exact test
Odds ratio
All infectious disease trials
903 results
- PREPAREIndependent statistical analysis of PREPARE (A5361s) Ancillary Study of REPRIEVE (A5332): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03070223).
- Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract: Complete Statistical AnalysisIndependent statistical analysis of Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- PREVACIndependent statistical analysis of PREVAC (NCT02876328), a randomized phase 2 Ebola vaccination trial evaluating antibody response through Month 12 using a stratified Cochran-Mantel-Haenszel analysis.
- PREVAILIndependent statistical analysis of A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection: primary endpoint results,…
- PREVENTIndependent statistical analysis of Prazosin to Prevent COVID-19 (PREVENT-COVID Trial): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04365257).
- PREVENT-HDA detailed statistical analysis of the phase 3 PREVENT-HD trial of rivaroxaban versus placebo in medically ill outpatients with acute symptomatic COVID-19 infection, including its time-to-event endpoints, hazard ratio, confidence interval, log-rank…
- PREVENT-HDIndependent statistical analysis of A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019…
- Preventing Sexual Transmission of HIV With Anti-HIV Drugs: Complete Statistical AnalysisIndependent statistical analysis of Preventing Sexual Transmission of HIV With Anti-HIV Drugs: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00074581).
- Preventing Staphylococcal (Staph) Infection: Complete Statistical AnalysisIndependent statistical analysis of Preventing Staphylococcal (Staph) Infection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00108160).
- Prevention of GBS Colonization Via Immunity: Complete Statistical AnalysisIndependent statistical analysis of Prevention of GBS Colonization Via Immunity: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00128219).
- Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study: Complete Statistical AnalysisIndependent statistical analysis of Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00381615).
- PRIDE-HTIndependent statistical analysis of PK Study of Rifampicin Interactions With DMPA and Efavirenz in TB: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Primary and Booster Vaccination Study With a Pneumococcal Vaccine in HIV Infected, HIV Exposed Uninfected and HIV Uninfected Children 6 to 10 Weeks of Age.: Complete Statistical AnalysisIndependent statistical analysis of Primary and Booster Vaccination Study With a Pneumococcal Vaccine in HIV Infected, HIV Exposed Uninfected and HIV Uninfected Children 6 to 10 Weeks of Age.: primary endpoint results,…
- Primary Vaccination Course in Children Receiving the Pneumococcal Vaccine GSK 1024850A, Zilbrix™ Hib and Polio Sabin™: Complete Statistical AnalysisIndependent statistical analysis of Primary Vaccination Course in Children Receiving the Pneumococcal Vaccine GSK 1024850A, Zilbrix™ Hib and Polio Sabin™: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- PRO 140 in Treatment-Experienced HIV-1 Subjects: Complete Statistical AnalysisIndependent statistical analysis of PRO 140 in Treatment-Experienced HIV-1 Subjects: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03902522).
- Project DRUMIndependent statistical analysis of Developing Rectal USPE Measures: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02102867).
- Prolonged Prone Positioning for COVID-19-induced Acute Respiratory Distress Syndrome (ARDS): Complete Statistical AnalysisIndependent statistical analysis of Prolonged Prone Positioning for COVID-19-induced Acute Respiratory Distress Syndrome (ARDS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04581811).
- PROMOTEIndependent statistical analysis of Communication Strategy to PROMOTE HPV Vaccination in Pharmacies: PROMOTE Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04660331).
- PROMOTE-PIsIndependent statistical analysis of Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant Women: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00993031).
- Promoting Altruism to Enhance Vaccine Acceptance: Complete Statistical AnalysisIndependent statistical analysis of Promoting Altruism to Enhance Vaccine Acceptance: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04568590).
- Propel Stent vs Kenalog-soaked Nasopore After Frontal Drill-out: Complete Statistical AnalysisIndependent statistical analysis of Propel Stent vs Kenalog-soaked Nasopore After Frontal Drill-out: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03534362).
- Prophylactic Antibiotics for Prevention of Wound Complications Following Vulvectomy: Complete Statistical AnalysisIndependent statistical analysis of Prophylactic Antibiotics for Prevention of Wound Complications Following Vulvectomy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00550290).
- Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size…
- Prophylactic Efficacy of Relenza Against Influenza A and B: Complete Statistical AnalysisIndependent statistical analysis of Prophylactic Efficacy of Relenza Against Influenza A and B: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01156701).
- Prophylactic Ivermectin in COVID-19 Contacts: Complete Statistical AnalysisIndependent statistical analysis of Prophylactic Ivermectin in COVID-19 Contacts: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04422561).
- Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients With Pentamidine: a Cohort Study: Complete Statistical AnalysisIndependent statistical analysis of Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients With Pentamidine: a Cohort Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- PROTECTIndependent statistical analysis of Project PROTECT: Protecting Nursing Homes From Infections and Hospitalization: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03118232).
- PROTEKTIndependent statistical analysis of Kaletra in Combination With Antiretroviral Agents: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01076179).
- PROVENTIndependent statistical analysis of Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors: Complete Statistical AnalysisIndependent statistical analysis of Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02950467).
- PURPOSE 2Independent statistical analysis of PURPOSE 2, a randomized phase 3 trial of lenacapavir for HIV pre-exposure prophylaxis, including its rate-based primary analyses, Poisson regression, Wald testing, confidence intervals, and statistical interpretation.
- PUSHIndependent statistical analysis of Pediatric Urgent Start of Highly Active Antiretroviral Treatment (HAART): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02063880).
- Pyronaridine Artesunate (3:1) in Children and Adults With Acute Plasmodium Vivax Malaria: Complete Statistical AnalysisIndependent statistical analysis of Pyronaridine Artesunate (3:1) in Children and Adults With Acute Plasmodium Vivax Malaria: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Qualitative Assessment of Implementing Routine Rapid HIV Testing: Complete Statistical AnalysisIndependent statistical analysis of Qualitative Assessment of Implementing Routine Rapid HIV Testing: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00680862).
- Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266): Complete Statistical AnalysisIndependent statistical analysis of Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- QUILT-3.009: Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC): Complete Statistical AnalysisIndependent statistical analysis of QUILT-3.009: Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Raltegravir Cerebrospinal Fluid Pharmacodynamic Study in HIV-Infected Individuals: Complete Statistical AnalysisIndependent statistical analysis of Raltegravir Cerebrospinal Fluid Pharmacodynamic Study in HIV-Infected Individuals: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01293123).
- Randomized Study of Immune Response to Licensed Influenza Vaccines in Children and Adolescents: Complete Statistical AnalysisIndependent statistical analysis of Randomized Study of Immune Response to Licensed Influenza Vaccines in Children and Adolescents: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Randomized Trial of Alternative HPV Vaccination Schedules in Males in a University Setting: Complete Statistical AnalysisIndependent statistical analysis of Randomized Trial of Alternative HPV Vaccination Schedules in Males in a University Setting: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Randomized Trial of Alternative Quadrivalent Human Papilloma Virus (HPV) Vaccination Schedules in a University Setting: Complete Statistical AnalysisIndependent statistical analysis of Randomized Trial of Alternative Quadrivalent Human Papilloma Virus (HPV) Vaccination Schedules in a University Setting: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Randomized, Open Label Safety Trial of Dapivirine Vaginal Ring and Oral TRUVADA® Use in Pregnancy: Complete Statistical AnalysisIndependent statistical analysis of Randomized, Open Label Safety Trial of Dapivirine Vaginal Ring and Oral TRUVADA® Use in Pregnancy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- RANIAIndependent statistical analysis of Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants…
- Rapid Diagnostic Assay for Gonorrhea and Chlamydia: Complete Statistical AnalysisIndependent statistical analysis of Rapid Diagnostic Assay for Gonorrhea and Chlamydia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05564299).
- RAS and Coagulopathy in COVID19: Complete Statistical AnalysisIndependent statistical analysis of RAS and Coagulopathy in COVID19: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04419610).
- RavLymeIndependent statistical analysis of Effect of Auricular Vagal Nerve Electrical Stimulation on Post-Treatment Lyme Disease Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- RE-CHUTIndependent statistical analysis of Relapse Rate in Hepatitis C Patients Treated With Peginterferon Alfa-2b Plus Ribavirin in Common Clinical Practice in France (P05484)(Completed): primary endpoint results, effect estimate with confidence interval, sample-size…
- Real World Study: Genotype 1 Chronic Hepatitis C Virus Treatment and Evaluation of Real World SVR and PRO: Complete Statistical AnalysisIndependent statistical analysis of Real World Study: Genotype 1 Chronic Hepatitis C Virus Treatment and Evaluation of Real World SVR and PRO: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- REALITYIndependent statistical analysis of the REALITY phase 3 trial (NCT01825031), including trial design, endpoints, planned analysis, factorial design, statistical methodology, and interpretation.
- RECOVERYIndependent statistical analysis of the RECOVERY phase 3 trial, including its factorial design, primary mortality and time-to-discharge endpoints, planned statistical methods, and interpretation of the trial design.
- Recurrent Bacterial Vaginosis and Vaginal Acidifying Gel Trial: Complete Statistical AnalysisIndependent statistical analysis of Recurrent Bacterial Vaginosis and Vaginal Acidifying Gel Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00545181).